ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0384

Inflammation Is Associated with Incident Hypertension in Patients with Axial Spondyloarthritis: A Longitudinal Cohort Study

Jenny Lin Hong Shi1, Steven H Lam2, Ho So3, Edmund Li1, Tena Li1, Cheuk Chun Szeto1 and Lai-shan Tam1, 1The Chinese University of Hong Kong, Hong Kong, China, 2The Chinese university of Hong Kong, Hong Kong, Hong Kong, 3The Faculty of Medicine, CUHK, Hong Kong, Hong Kong

Meeting: ACR Convergence 2022

Keywords: Cardiovascular, Disease Activity, Disease-Modifying Antirheumatic Drugs (Dmards), Inflammation, spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: In the general population, hypertension (HT) is reported as one of the most important risk and modifiable factors to develop CVD. It is well recognized that inflammatory rheumatic diseases had increased risk of cardiovascular disease (CVD) burden. But limited studies exploring the relationship between axial spondyloarthritis (axSpA) and hypertension (HT) were reported.

Methods: This is a retrospective cohort study performed in axSpA patients who were recruited from 2001-2019 in the rheumatology clinic of PWH. Patients with established HT diagnosis and/or anti-hypertensives at baseline were excluded. They were followed from 2001 to 2020, till the occurrence of first diagnosis of IHT or end of study or the loss of follow-up. Baseline clinical and demographic data, drug history and traditional CV risk factors were compared between groups with and without IHT. Baseline and time-varying Cox regression analyses adjusting for age, sex, and BMI, were used to assess the relationship between drug history, inflammatory burden and IHT.

Results: 413 patients [34(25-43) years, male: 319 (77.2%)] were recruited. After a median follow up of 12 (6-17) years, 58 patients (14%) developed IHT (IHT+group). At baseline, in the multivariable Cox regression model, only baseline disease duration was an independent predictor for IHT. In the time-varying univariable Cox regression, increased ESR level and high inflammatory state (ESR≧20) over time were significant predictors for the development of IHT. Regarding drug use, paracetamol as well as use of csDMARDs, especially sulfasalazine were significantly associated with a higher risk of developing IHT (p< 0.001). While in multivariate analysis, baseline disease duration remained as the only significant predictor to increase risk of future IHT. ESR as an inflammatory marker had only borderline statistical significance in predicting the development of IHT, while ESR³20, the use of csDMARDs or sulfasalazine or paracetamol were no longer statistically significant.

Conclusion: Higher inflammatory burden as reflected by a longer baseline disease duration was a predictor associated with IHT after adjusting for traditional CV risk factors. Higher ESR level may also play a role in the development of IHT in these patients.

Supporting image 1

Table 1. Multivariable analysis with Cox proportional hazard regression for baseline predictors of IHT.

Supporting image 2

Table 2. Univariable analysis with time-dependent Cox proportional hazard regression for the predictors of incident hypertension (IHT).

Supporting image 3

Table 3. Multivariable analysis with time-dependent Cox proportional hazard regression for the predictors of IHT.


Disclosures: J. Shi, None; S. Lam, None; H. So, None; E. Li, None; T. Li, None; C. Szeto, None; L. Tam, AbbVie, Amgen, Boehringer-Ingelheim, Eli Lilly, GlaxoSmithKlein(GSK), Janssen, Novartis, Pfizer, Sanofi, AstraZeneca.

To cite this abstract in AMA style:

Shi J, Lam S, So H, Li E, Li T, Szeto C, Tam L. Inflammation Is Associated with Incident Hypertension in Patients with Axial Spondyloarthritis: A Longitudinal Cohort Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/inflammation-is-associated-with-incident-hypertension-in-patients-with-axial-spondyloarthritis-a-longitudinal-cohort-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammation-is-associated-with-incident-hypertension-in-patients-with-axial-spondyloarthritis-a-longitudinal-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology